Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications (Q35102465)

6 August 2017

1 reference

title

Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications (English)

1 reference

6 August 2017

1 reference

Sahebarao P Mahadik

1

1 reference

PubMed ID

12683261

6 August 2017

Denise R Evans

series ordinal

2

1 reference

6 August 2017

1 March 2003

1 reference

Psychiatric Clinics of North America

6 August 2017

1 reference

6 August 2017

26

1 reference

6 August 2017

1

1 reference

6 August 2017

85-102

1 reference

The membrane hypothesis of schizophrenia

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Schizophrenia as a membrane lipid disorder which is expressed throughout the body

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Free radical pathology and antioxidant defense in schizophrenia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Receptor-mediated activation of phospholipase A2 and arachidonic acid release in signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Fatty acid levels in the brains of schizophrenics and normal controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Erythrocyte membrane phospholipids in psychotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Fat consumption and schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

High fat diets varying in ratios of polyunsaturated to saturated fatty acid and linoleic to linolenic acid: a comparison of rat neural and red cell membrane phospholipids.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Biochemical and functional effects of prenatal and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Docosahexaenoic acid is the preferred dietary n-3 fatty acid for the development of the brain and retina

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Omega-3 fatty acids in health and disease and in growth and development

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Do essential fatty acids play a role in brain and behavioral development?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Frontal lobe metabolism and cerebral morphology in schizophrenia: 31P MRS and MRI studies

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Region-specific changes in phospholipid metabolism in chronic, medicated schizophrenia: (31)P-MRS study at 4.0 Tesla

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

No differences in phospholipase-A2 activity between acute psychiatric patients and controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Free radical pathology in schizophrenia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Elevated plasma lipid peroxides at the onset of nonaffective psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Accumulation of diacylgylcerol in platelet phosphoinositide turnover in schizophrenia: a biological marker of good prognosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

The platelet polyphosphoinositide system in schizophrenia: the effects of neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Increased turnover of platelet phosphatidylinositol in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Information processing and attention dysfunctions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Peroxidation induced changes in synaptosomal transport of dopamine and gamma-aminobutyric acid

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Regulation of gamma-aminobutyric acid/barbiturate receptor-gated chloride ion flux in brain vesicles by phospholipase A2: possible role of oxygen radicals.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Vitamin E treatment of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900033-3

7 January 2021

10.1016/S0193-953X(02)00033-3

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12683261